Liver fibrosis / NASH

BIOCELLVIA’S NASH ASSAY

Nonalcoholic steatohepatitis (NASH) occurs in close association with obesity and type 2 diabetes emerging as the most common chronic liver disease. It progresses to severe hepatic diseases including cirrhosis, liver failure and hepatocellular carcinoma. Morphometric quantitative analysis of NASH from histological images of liver slices remains highly problematic up to now, due to the scarcity of specific, accurate and powerful analytical tools. Biocellvia has successfully developed a NASH assay which enables highly precise analysis of steatosis, fibrosis and inflammation.

FEATURES OF BIOCELLVIA’S NASH ASSAY

  • Biocellvia’s assay is based on computer analysis of digital images of entire liver sections at high resolution (pixel size: 0.452 µm), obtained from the scan of histological slides. An automatic selection of steatosis, fibrosis and inflammation is performed on liver sections according to specific morphometric parameters.
  • Quantitative morphometric analysis of steatosis and fibrosis is performed by assessing multiple key morphometric parameters:

 

Key parameters : 

 

Additional parameters :

1- Quantification of steatosis
2- Quantification of fibrosis 
3- Quantification of inflammation
4- Distribution of vacuole size
5- Mean vacuole size

combined with a quantitative analysis of inflammation by means of immunolabeling of inflammatory markers.

  • The assessment of multiple morphometric parameters has been validated as endpoint measurements in several rodent models in which they were compared with standard measurements.
  • The quantification of NASH is fully automatic from the scanning of slides to the complete evaluation of morphometric parameters and statistical analysis. This analysis is very rapid (<2h for 100 whole lung sections) and avoids any intra- and inter-variabilities from the subjective evaluation of the experimenter.

1- Quantification of steatosis

Figure 1 & 2. Steatosis can be assessed with hematoxylin eosin upper panel or picrosirius red stain slide lower panel. For those panels, from left to right there are a control image, then an early NASH stage and a late NASH stage which have been processed as shown in the zoom.

Biocellvia quantifies steatosis and measures the mean vacuole size on liver sections with NASH and NAFLD
Distribution of vacuole size (liver fibrosis)

2- Quantification of fibrosis

  • The density of fibrosis was assessed following the discrimination of collagen fibers
  • Notable increase of collagen content at early (18 weeks) and late (32 weeks) stage NASH. In control animals, collagen fibers display only a perivascular distribution.
Biocellvia quantifies liver fibrosis thanks to collagen fibers

3- Quantification of inflammation

Biocellvia technology quantifies inflammation thanks to F4/80 than detects crownline structures

To examine the level of inflammation in NASH, a fully-automated quantification of active macrophages immunolabelled by F4/80 was conducted on the entire liver sections of Foz/Foz mice.

TOP 3 REASONS TO CHOOSE BIOCELLVIA’S NASH ASSAY

  • Biocellvia’s NASH assay is a fully automatic software analysis, totally observer-independentand therefore free of any intra- and inter-experimental variabilities.
  • Quantitative assessment of NASH is performed by matching multiple morphometric parameters leading to a significantly more comprehensive analysis of liver structural changes than the current standard methods.
  • Biocellvia’s NASH assay overcomes the current standard methods, based on scoring evaluation, in terms of accuracy, reliability, reproducibility and rapidity.

Biocellvia’s cutting-edge digital NASH assay is unparalleled in its robustness and accuracy, and is your best and most reliable choice in preclinical drug evaluation, empowering your Go/No decisions.

Feel free to contact us to get more information